A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

NCT04113551 · clinicaltrials.gov ↗

COMPLETED

Status

17418

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: MPH (Concerta)
DRUG: MPH (Ritalin)
DRUG: Atomoxetine (ATO)
DRUG: Guanfacine (GFC)

Sponsor

Janssen Research & Development, LLC